OBLN
Obalon Therapeutics, Inc. [OBLN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
OBLN Stock Summary
In the News
OBLN Financial details
Company Rating
Buy
Market Cap
5.47M
Income
-7.06M
Revenue
108.53K
Book val./share
6.15
Cash/share
4.25
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
12 May 2021
P/E
-1.92
Forward P/E
-
PEG
0.23
P/S
26778128.7
P/B
5.08
P/C
0.72
P/FCF
-0.52
Quick Ratio
1.4
Current Ratio
1.55
Debt / Equity
0.02
LT Debt / Equity
-
-
-
EPS (TTM)
-0.81
EPS next Y
-
EPS next Q
-
EPS this Y
-68.39%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-49.51%
Revenue last 5Y
-14.09%
Revenue Q/Q
-
EPS Q/Q
-99.91%
-
-
-
-
SMA20
-37.5%
SMA50
-37.5%
SMA100
-
Inst Own
19.91%
Inst Trans
0.87%
ROA
-116%
ROE
-120%
ROC
-1.91%
Gross Margin
37%
Oper. Margin
-670%
Profit Margin
-777%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.948-4.8
52W High
-23.75%
52W Low
+52.5%
RSI
42
Rel Volume
17.55
Avg Volume
1.51M
Volume
26.47M
Perf Week
-44.85%
Perf Month
-57.99%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
-1.24035
-
-
Volatility
0.61%, 2.38%
Prev Close
-39%
Price
3.05
Change
-29.56%
OBLN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
| Metric | History | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 8.04 | 5.93 | 4.78 | 0.7 | 0.2 | |
| Net income per share | -48.48 | -20.8 | -19.64 | -5.03 | -1.59 | |
| Operating cash flow per share | -45.88 | -18.32 | -15.46 | -4.86 | -1.34 | |
| Free cash flow per share | -46.71 | -18.94 | -16.13 | -4.9 | -1.36 | |
| Cash per share | 178.77 | 26.56 | 12.47 | 2.99 | 0.5 | |
| Book value per share | 152.31 | 21 | 6.89 | 3.37 | 0.6 | |
| Tangible book value per share | 152.31 | 21 | 6.89 | 3.37 | 0.6 | |
| Share holders equity per share | 152.31 | 21 | 6.89 | 3.37 | 0.6 | |
| Interest debt per share | 23.4 | 5.94 | 5.22 | 0 | 1.33 | |
| Market cap | 3.74M | 11.05M | 3.94M | 8.94M | 11.66M | |
| Enterprise value | -56.86M | -136K | -7.32M | -3.98M | 18.11M | |
| P/E ratio | -0.18 | -0.32 | -0.11 | -0.38 | -0.95 | |
| Price to sales ratio | 1.1 | 1.11 | 0.43 | 2.73 | 7.34 | |
| POCF ratio | -0.19 | -0.36 | -0.13 | -0.39 | -1.12 | |
| PFCF ratio | -0.19 | -0.35 | -0.13 | -0.39 | -1.1 | |
| P/B Ratio | 0.06 | 0.31 | 0.3 | 0.56 | 2.5 | |
| PTB ratio | 0.06 | 0.31 | 0.3 | 0.56 | 2.5 | |
| EV to sales | -16.76 | -0.01 | -0.8 | -1.21 | 11.4 | |
| Enterprise value over EBITDA | 2.8 | 0 | 0.2 | 0.17 | -1.58 | |
| EV to operating cash flow | 2.94 | 0 | 0.25 | 0.17 | -1.74 | |
| EV to free cash flow | 2.88 | 0 | 0.24 | 0.17 | -1.71 | |
| Earnings yield | -5.48 | -3.15 | -9.49 | -2.65 | -1.06 | |
| Free cash flow yield | -5.28 | -2.87 | -7.79 | -2.58 | -0.91 | |
| Debt to equity | 0.15 | 0.28 | 0.76 | 0 | 2.22 | |
| Debt to assets | 0.13 | 0.19 | 0.33 | 0 | 0.98 | |
| Net debt to EBITDA | 2.99 | 0.32 | 0.31 | 0.57 | -0.56 | |
| Current ratio | 17 | 5.17 | 1.66 | 4.59 | 1.55 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.95 | 0.88 | 0.79 | 0.97 | 0.84 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 3.01 | 2.91 | 3.29 | 5.08 | 5.53 | |
| Research and developement to revenue | 2.91 | 1.07 | 1.18 | 2.1 | 1.54 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0.03 | 0.04 | 0.01 | 0.02 | |
| Capex to revenue | -0.1 | -0.11 | -0.14 | -0.06 | -0.11 | |
| Capex to depreciation | -1.83 | -3.16 | -2.21 | -0.22 | -0.2 | |
| Stock based compensation to revenue | 0.17 | 0.33 | 0.52 | 0.91 | 0.69 | |
| Graham number | 407.6 | 99.14 | 55.15 | 19.52 | 4.63 | |
| ROIC | -0.25 | -0.76 | -1.59 | -1.44 | -0.61 | |
| Return on tangible assets | -0.26 | -0.65 | -1.23 | -1.16 | -1.16 | |
| Graham Net | 146.39 | 18.16 | 4.15 | 2.27 | 0.04 | |
| Working capital | 73.47M | 41.74M | 11.42M | 14.26M | 2.79M | |
| Tangible asset value | 64.31M | 35.11M | 13.11M | 15.85M | 4.67M | |
| Net current asset value | 63.59M | 33.77M | 11.37M | 13.69M | 1.88M | |
| Invested capital | 0.15 | 0.28 | 0.76 | 0 | 2.22 | |
| Average receivables | 590.5K | 2.41M | 2.6M | 583.5K | 1.72M | |
| Average payables | 572K | 935.5K | 1.22M | 903.5K | 631.5K | |
| Average inventory | 595K | 1.12M | 1.5M | 1.76M | 968K | |
| Days sales outstanding | 55.94 | 158.61 | 35.37 | 31.71 | 724.02 | |
| Days payables outstanding | 77.31 | 96.45 | 78.01 | 80.18 | 223.58 | |
| Days of inventory on hand | 107.46 | 107.18 | 106.34 | 239.54 | 0 | |
| Receivables turnover | 6.53 | 2.3 | 10.32 | 11.51 | 0.5 | |
| Payables turnover | 4.72 | 3.78 | 4.68 | 4.55 | 1.63 | |
| Inventory turnover | 3.4 | 3.41 | 3.43 | 1.52 | 0 | |
| ROE | -0.32 | -0.99 | -2.85 | -1.49 | -2.64 | |
| Capex per share | -0.83 | -0.62 | -0.67 | -0.04 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2021-06-30 for Q2
| Metric | History | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.09 | 0.01 | 0.01 | 0 | 0 | |
| Net income per share | -0.54 | -0.2 | -0.17 | -0.44 | 0 | |
| Operating cash flow per share | -0.36 | -0.17 | -0.2 | -0.47 | 0.03 | |
| Free cash flow per share | -0.33 | -0.17 | -0.21 | -0.47 | 0.01 | |
| Cash per share | 0.88 | 0.71 | 0.5 | 0.95 | 4.25 | |
| Book value per share | 0.93 | 0.77 | 0.6 | 1.07 | 6.15 | |
| Tangible book value per share | 0.93 | 0.77 | 0.6 | 1.07 | 0.8 | |
| Share holders equity per share | 0.93 | 0.77 | 0.6 | 1.07 | 6.15 | |
| Interest debt per share | 0.06 | 0.06 | 0.7 | 0.03 | 0.14 | |
| Market cap | 5.45M | 7.04M | 11.66M | 26.63M | 28.8M | |
| Enterprise value | 324.32K | 3.09M | 13.18M | 17.97M | -10.69M | |
| P/E ratio | -0.33 | -1.13 | -2.2 | -1.6 | -1.85K | |
| Price to sales ratio | 7.76 | 159.91 | 191.08 | 0 | 8.16K | |
| POCF ratio | -1.98 | -5.45 | -7.5 | -6 | 98.31 | |
| PFCF ratio | -2.15 | -5.45 | -7.24 | -6 | 296.96 | |
| P/B Ratio | 0.76 | 1.19 | 2.5 | 2.64 | 0.5 | |
| PTB ratio | 0.76 | 1.19 | 2.5 | 2.64 | 0.5 | |
| EV to sales | 0.46 | 70.19 | 216.08 | 0 | -3.03K | |
| Enterprise value over EBITDA | -0.08 | -2.29 | -11.77 | -4.49 | 82.23 | |
| EV to operating cash flow | -0.12 | -2.39 | -8.48 | -4.05 | -36.5 | |
| EV to free cash flow | -0.13 | -2.39 | -8.19 | -4.05 | -110.25 | |
| Earnings yield | -0.77 | -0.22 | -0.11 | -0.16 | 0 | |
| Free cash flow yield | -0.47 | -0.18 | -0.14 | -0.17 | 0 | |
| Debt to equity | 0.06 | 0.07 | 1.16 | 0.03 | 0.02 | |
| Debt to assets | 0.03 | 0.04 | 0.51 | 0.02 | 0.01 | |
| Net debt to EBITDA | 1.29 | 2.93 | -1.36 | 2.16 | 303.73 | |
| Current ratio | 1.92 | 1.79 | 1.55 | 1.86 | 1.08 | |
| Interest coverage | 0 | 0 | 0 | 0 | 21.52K | |
| Income quality | 0.66 | 0.83 | 1.17 | 1.07 | -75.09 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 3.36 | 0 | 20.16 | 0 | 1.22 | |
| Research and developement to revenue | 1.09 | 6.16 | 2.57 | 0 | 0.03 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0.42 | |
| Capex to operating cash flow | -0.08 | 0 | 0.03 | 0 | -0.67 | |
| Capex to revenue | 0.3 | 0 | -0.89 | 0 | -55.54 | |
| Capex to depreciation | 1.04 | 0 | -0.26 | 0 | 1.56 | |
| Stock based compensation to revenue | 0.42 | 5.89 | 1.11 | 0 | -100.31 | |
| Graham number | 3.37 | 1.87 | 1.52 | 3.26 | 0.24 | |
| ROIC | -0.25 | -0.25 | -0.13 | -0.4 | -0.06 | |
| Return on tangible assets | -0.3 | -0.13 | -0.12 | -0.24 | 0 | |
| Graham Net | 0.32 | 0.24 | 0.04 | 0.43 | -1.87 | |
| Working capital | 5.18M | 3.98M | 2.79M | 5.93M | 5.11M | |
| Tangible asset value | 7.18M | 5.92M | 4.67M | 10.1M | 7.57M | |
| Net current asset value | 4.08M | 2.99M | 1.88M | 5.55M | 3.72M | |
| Invested capital | 0.06 | 0.07 | 1.16 | 0.03 | 0.02 | |
| Average receivables | 3.38M | 3.15M | 3.15M | 3.15M | 3.29M | |
| Average payables | 1.06M | 855K | 635.5K | 598.5K | 1.84M | |
| Average inventory | 704K | 0 | 0 | 0 | 1.45M | |
| Days sales outstanding | 403.27 | 6.44K | 4.65K | 0 | 87.27K | |
| Days payables outstanding | 224.26 | 1.44K | 55.35K | 0 | 202.43K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 189.29K | |
| Receivables turnover | 0.22 | 0.01 | 0.02 | 0 | 0 | |
| Payables turnover | 0.4 | 0.06 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.58 | -0.26 | -0.28 | -0.41 | 0 | |
| Capex per share | 0.03 | 0 | -0.01 | 0 | -0.02 |
OBLN Frequently Asked Questions
What is Obalon Therapeutics, Inc. stock symbol ?
Obalon Therapeutics, Inc. is a US stock , located in Carlsbad of California and trading under the symbol OBLN
What is Obalon Therapeutics, Inc. stock quote today ?
Obalon Therapeutics, Inc. stock price is $3.05 today.
Is Obalon Therapeutics, Inc. stock public?
Yes, Obalon Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.51M
- Market Capitalization 5.47M
- Employee 2
- CEO Dr. Kelly Huang
- Headquarters Carlsbad,CALIFORNIA,US
- IPO Date 2016-10-06
-
Website
http://www.obalon.com 
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallow able capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. As of February 27, 2020, it had three company-managed retail treatment centers in California. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
